Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Takeda disclosed recently that Swiss partner Santhera has commenced a pivotal Phase III trial for Catena/Sovrima (idebenone), which could be the first drug to treat Duchenne Muscular Dystrophy, a rare disease that affects an estimated 30,000 European and North American male patients mainly in their teens
You may also be interested in...
Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).